Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05850234 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

NCT05850234 · ClinicalTrials.gov record · last posted 2026-08-17

AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)

Name: AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1) — clinical trial record (NCT05850234)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: DURGA-1

StatusRecruiting

PhasePhase 1/2

SponsorAstraZeneca

Started2023-07-20

View on ClinicalTrials.gov ↗

from the ClinicalTrials.gov record

This trial is a Phase 1b/2, open-label, multicenter study of AZD0120, a CD19/BCMA dual CAR T-cell therapy, in adult subjects with relapsed/refractory multiple myeloma.

Protocol amendment history 3 changes detected by DataLookout

2026-08-18

Enrollment increased: 182 → 232 participants

2026-08-18

Primary completion pushed: 2027-08-31 → 2027-10-01

2026-08-18

Completion pushed: 2028-11-14 → 2029-01-25

Trial Details

NCT Number	NCT05850234
Lead Sponsor	AstraZeneca
Conditions	Relapsed/Refractory Multiple Myeloma
Enrollment	232 participants
Start Date	2023-07-20
Primary Completion	2027-10-01 (estimated)
Study Completion	2029-01-25 (estimated)
Updated on ClinicalTrials.gov	2026-08-17